Adding compounded weight loss injectables like tirzepatide or semaglutide to your medspa menu compliantly means lining up a licensed prescriber's order, a good faith exam for every patient, a 503A or 503B pharmacy source, and documented medical director oversight before you list the service in 2026. Skip any one of those four pieces and the menu addition becomes the reason a state board opens a file on your practice.
- Compounded tirzepatide and semaglutide need a prescriber’s order, a good faith exam, and medical director sign-off before launch in 2026.
- Source compounded GLP-1s only from a licensed 503A or 503B pharmacy – unlicensed sourcing is the fastest way to lose your menu.
- US Medical Directors’ collaborating physician and good faith exam services cover the oversight most medspas skip when adding weight loss injectables.
- Standing orders and chart review cadence differ by state, not by which GLP-1 you compound. Check your board before you price the service.
Why this matters
Compounded GLP-1s are the fastest-growing line item on medspa menus in 2026, and they're also the line item most likely to draw board attention. Compounding sits outside FDA approval, which means the burden of proof for medical necessity, sourcing, and supervision falls entirely on the practice adding the service.
A nurse or aesthetician who adds tirzepatide to the menu without a documented collaborating physician relationship isn't just risking a fine. Boards in multiple states have suspended licenses over unsupervised weight loss injectable programs, and malpractice carriers routinely deny claims when the required exam or oversight documentation doesn't exist. US Medical Directors works with medspas building compliant weight loss verticals across many states, and the same four requirements show up every time.
How to add compounded weight loss injectables to your medspa menu compliantly
Follow these steps in order. Jumping to sourcing before you've confirmed supervision rules is the single most common mistake medspa owners make when launching a GLP-1 line.
- Confirm your state's supervision requirements first. Some states let nurse practitioners prescribe and order compounded GLP-1s independently; others require a collaborating physician agreement or a formal medical director relationship before a single patient is seen. Determine if your state requires a medical director before you commit to a launch date.
- Line up a licensed prescriber or collaborating physician. The physician needs to be actively licensed in the state where treatment happens, not just where your business is registered.
- Source compounded product from a licensed 503A or 503B pharmacy only. Verify the pharmacy's state board registration and FDA registration status directly. Don't take a sales rep's word for it.
- Run a good faith exam on every new weight loss patient. Good faith exams for semaglutide clinics establish medical necessity and screen for contraindications such as a personal or family history of medullary thyroid cancer before the first injection.
- Build standing orders that name the specific compounded drugs, dosing protocols, and escalation criteria. Generic weight loss injectable language does not hold up under a board review. Protocols need to name tirzepatide and semaglutide specifically and spell out titration schedules.
- Set a chart review cadence with your medical director and put it in writing, including how often charts get reviewed and what triggers an off-cycle review.
- Document everything from day one. Boards ask for records going back to the first patient, not just the last six months.
Compounded GLP-1 sourcing paths compared
| Sourcing path | Prescriber requirement | Oversight requirement | Best for |
|---|---|---|---|
| 503A compounding pharmacy | Patient-specific prescription required | Good faith exam plus standing order per patient | Solo medspas with lower patient volume |
| 503B outsourcing facility | Office-use ordering permitted in most states | Medical director sign-off on bulk orders | Multi-location groups and higher-volume clinics |
| Brand-name GLP-1 (Zepbound, Wegovy) | Standard prescription | Same exam and chart documentation standard | Practices avoiding compounding scrutiny entirely |
Verdict: medspas adding compounded weight loss injectables in 2026 need a collaborating physician relationship and a documented good faith exam workflow before sourcing decisions matter at all. Supervision gaps get flagged before sourcing gaps do.
Why compliance requirements vary by state and practice type
- Nurse practitioner scope-of-practice laws determine whether an NP can prescribe compounded GLP-1s independently or needs a collaborating physician's signature on every order.
- State board classification of compounded drugs changes documentation requirements. Some boards treat compounded tirzepatide like any other prescription; others require extra informed consent language specific to compounding.
- Telehealth vs in-person exam rules decide whether the good faith exam can happen by video or requires a physical visit, and this varies significantly state to state.
- Malpractice carrier requirements often exceed the state minimum. Carriers frequently require documented medical director oversight even where it isn't legally mandatory.
- Pharmacy licensing status (503A vs 503B) changes whether office-use stock is legal in your state, which affects how you structure inventory and per-patient charting.
- Multi-location ownership adds a layer: a collaborating physician licensed in one state doesn't cover a second location in a different state without a separate agreement.
Get oversight for your GLP-1 menu
Collaborating physician and good faith exam support built for aesthetic practices.
Do you need a good faith exam for every tirzepatide patient?
Yes, a good faith exam is required for every new tirzepatide patient before the first injection, not just once per calendar year. The exam establishes medical necessity, screens contraindications, and creates the record a board or malpractice carrier will ask for if anything goes wrong. Documenting good faith exams for tirzepatide patients is what turns that visit into defensible evidence rather than a note nobody can find in 2026.
Can a nurse practitioner prescribe compounded semaglutide without a collaborating physician?
It depends entirely on the state. Full practice authority states let NPs prescribe independently; reduced and restricted practice states require a signed collaborating physician agreement before any compounded GLP-1 order goes out. Checking your own state board rule matters more than copying what the medspa one state over is doing, because two adjacent states can have opposite answers.
How often does a medical director need to review weight loss injectable charts?
Chart review cadence for weight loss injectable patients should match the cadence written into your medical director agreement, and that cadence has to be written down rather than assumed. Practices running higher volume on compounded tirzepatide or semaglutide typically set a tighter schedule than practices offering the service occasionally, and the agreement should spell out what triggers an off-cycle review.
What does a compliant GLP-1 patient file contain?
A compliant file for a compounded weight loss injectable patient in 2026 contains the good faith exam note, the signed informed consent covering compounding, the prescriber's order naming the drug and dose, the pharmacy source record, the titration log, and the medical director's chart review signature. Any one of those missing turns a routine inspection into a finding.
“Boards rarely flag injection technique. They flag the missing signature on the standing order.”
FAQ
What do you need before adding compounded tirzepatide to a medspa menu?
You need a licensed prescriber or collaborating physician, a good faith exam workflow, a licensed 503A or 503B pharmacy source, and documented medical director oversight before listing compounded tirzepatide on the menu in 2026.
Is compounded semaglutide legal to offer at a medspa?
Compounded semaglutide is legal when sourced from a licensed 503A or 503B pharmacy under a valid patient-specific or office-use order, with a good faith exam and prescriber oversight documented for every patient.
Do medspas need a medical director for weight loss injectables specifically?
Most states require some form of physician or collaborating physician oversight for weight loss injectable programs, even where estheticians perform other services without one. Confirm your specific state board rule before launching.
What happens if a medspa skips the good faith exam for GLP-1 patients?
Skipping the good faith exam removes the documented medical necessity record a board or malpractice carrier requires. It is one of the fastest ways a weight loss injectable program draws an investigation.
Can one collaborating physician cover multiple medspa locations offering GLP-1s?
One collaborating physician can cover multiple locations only when licensed in each state where treatment happens and when the agreement names each location. A single-state agreement does not extend automatically.
How is compounded tirzepatide different from brand-name Zepbound for compliance purposes?
Compounded tirzepatide requires sourcing from a licensed 503A or 503B pharmacy and often carries extra informed consent requirements. Brand-name Zepbound follows standard prescription rules with the same exam and documentation standard.
Does telehealth change the good faith exam requirement for weight loss injectables?
Telehealth changes where the good faith exam can happen, not whether it is required. Some states allow video exams for weight loss injectable patients while others require an in-person visit.
How much medical director oversight does a new GLP-1 program need at launch?
At launch, oversight covers the standing orders, the good faith exam protocol, and a defined chart review schedule. Volume determines review frequency, not the drug itself.
One last thing
The practices that get flagged in 2026 almost never get flagged for injection technique. They get flagged for a missing signature on a standing order or a good faith exam written up after the fact. Build the documentation trail before the first patient, not after the first board inquiry.
Related guides
- How to set up standing orders for weight loss injectable programs
- Chart review services for tirzepatide weight loss clinics
